Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] February 2026 Private Placement February 2026 Private Placement [Member] February 2026 Private Placement Fair value change in instruments measured at fair value Gain (Loss) on Derivative Instruments, Gross, Pretax Gain (Loss) on Derivative Instruments, Gross, Pretax 2020 Equity Incentive Plan Equity Incentive Plan 2020 [Member] Information related to 2020 equity incentive plan. Number of shares used in per share calculations: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Trading Arrangement: Trading Arrangement [Axis] Outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Remaining Contractual Term Maximum Maximum [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Title of 12(b) Security Title of 12(b) Security Subsequent Event Subsequent Event [Member] Adjusted diluted net loss Net Income (Loss) Available to Common Stockholders, Diluted Document Fiscal Year Focus Document Fiscal Year Focus Private Offering Private Offering [Member] A private offering in which common stock is offered and sold on a firm commitment basis through one or more underwriters, all pursuant to (i) an effective registration statement under the Securities Act and (ii) an placement agency agreement between the Company and such agent. Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument [Axis] Financial Instrument [Axis] Conversion of stock (in shares) Conversion of Stock, Shares Issued Common stock, par value $0.0001; 250,000,000 and 125,000,000 shares authorized as of June 30, 2026 and December 31, 2025, respectively; 82,647,946 and 69,894,507 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively. Common Stock, Value, Issued Compensation and benefits Employee-related Liabilities, Current Deferred Compensation Plan Retirement Benefits [Text Block] Fair value liability, period decrease Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Restatement Determination Date Restatement Determination Date Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Maturities of Long-Term Debt [Abstract] Maturities of Long-Term Debt [Abstract] Conversion Of Convertible Preferred Stock Conversion Of Convertible Preferred Stock [Member] Conversion Of Convertible Preferred Stock Vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures March 2025 Financings March 2025 Financings [Member] March 2025 financing company entered into an underwriting agreement with Craig-Hallum Capital Group, LLC, as the sole underwriter. Warrants issued (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Less: Change in fair value of March 2025 Warrants and March 2025 Private Placement Warrants Dilutive Securities, Effect on Basic Earnings Per Share Amendment Flag Amendment Flag Current liabilities: Liabilities, Current [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Class of Warrant or Right [Table] Class of Warrant or Right [Table] Change in fair value Fair Value Adjustment of Warrants Debt instrument conversion, price percent Debt Instrument, Convertible, Share Purchase Price, Percent Debt Instrument, Convertible, Share Purchase Price, Percent Warrants Outstanding [Abstract] Warrants and Rights Note Disclosure [Abstract] Conversion shares Conversion Shares [Member] Conversion Shares Related Party Transactions Related Party Transactions Disclosure [Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Entity Address, State or Province Entity Address, State or Province Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross PEO Total Compensation Amount PEO Total Compensation Amount Common stock par value (in USD per share) Common Stock, Par or Stated Value Per Share Issuance of common stock and pre-funded warrants in connection with the March 2025 offering and private placement Stock Issued During Period Value of Private Offering and Private Placement Equity impact of the value of new stock issued in connection with private offering and private placement during the period. Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Accrued expenses Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Basic weighted average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Retirement Benefits [Abstract] Retirement Benefits [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2033 Long-Term Debt, Maturity, Year Seven Long-Term Debt, Maturity, Year Seven Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Maximum amount of payments receivable for development, regulatory and commercial milestones Maximum Amount Of Payments Receivable for Development, Regulatory and Commercial Milestones Milestone payments receivable upon the achievement of development, regulatory and commercial goals. Issuance costs related to financing activities Warrant Financing Costs Reclassified to Financing Activities The amount warrant financing costs reclassified to financing activities. Balance as of beginning of period Balance as of end of period Derivative Liability, Current Entity Address, City or Town Entity Address, City or Town Underwriting discounts, commissions and offering expenses Underwriting Discounts Commissions and Offering Expenses The amount of underwriting discounts, commissions and offering expenses. License Transfer Fee License Transfer Fee [Member] License transfer fee related to terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others. Issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Number of annual installments Debt Instrument, Number Of Installments Number of installments to paid monthly for the loan repayment. 2032 Long-Term Debt, Maturity, Year Six Long-Term Debt, Maturity, Year Six Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Title and Position [Domain] Title and Position [Domain] Iveric Agreement Iveric Asset Purchase Agreement [Member] Opus entered into an asset purchase agreement with Iveric (the "Iveric Agreement") pursuant to which the Company acquired certain assets, including the BEST1 License (as defined below), relating to the BEST1 and RHO products. Third Tranche Third Tranche [Member] Third Tranche Payment of final installment amount upon termination of agreement Payment of Final Installment upon Termination of Agreement The aggregate amount paid by the entity related to 2022 Binding Letter Agreement upon its termination. Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Nature of Business and Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Reconciliation of Contract Asset assets and Unbilled Receivables Schedule of Reconciliation of Contract Asset Associated [Table Text Block] Tabular disclosure of the reconciliation using contract asset associated with agreement. Maximum amount of loan Maximum Amount Funded to Support Study The maximum amount funded to support the study. Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Debt issuance costs Debt Issuance Costs, Gross Level 2 Fair Value, Inputs, Level 2 [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Reclassification to Accounts receivable related to costs billed under the Viatris License Agreement Contract Asset, Reclassification to Accounts Receivable Related to Costs Billed under License Agreement This line item represents amounts invoiced that were previously reflected in the Contract Asset account. Number of distinct performance obligations Number Of Performance Obligations The number of performance obligations in accordance with the provisions under ASC 606, the Company identified. Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Apexian Sublicense Agreement Apexian Sublicense Agreement [Member] Sublicense agreement with Apexian Pharmaceuticals, Inc. Summary of Significant Accounting Policies New Accounting Pronouncements, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Employer contribution Defined Contribution Plan, Employer Discretionary Contribution Amount Conversion Of Stock Purchase And Conversion Agreement Conversion Of Stock Purchase And Conversion Agreement [Member] Conversion Of Stock Purchase And Conversion Agreement Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Axis] Exercisable at beginning of period (in shares) Exercisable at end of period (in shares) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable In Period The number of exercisable made during the period on other than stock (or unit) option plans. Liabilities Measured at Fair Value on a Recurring Basis Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Long-term debt Total principal payments Long-Term Debt Proceeds from debt, net of issuance costs Proceeds from Debt, Net of Issuance Costs Document Period End Date Document Period End Date Change in assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Preferred stock outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Preferred Stock, Shares Outstanding Health Care Organization, Revenue Sources [Domain] Health Care Organization, Revenue Sources [Domain] Net (Loss) Income Per Share [Abstract] Earnings Per Share, Basic [Abstract] Conversion of Stock, Name [Domain] Conversion of Stock, Name [Domain] Temporary equity, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Temporary Equity, Shares Outstanding Security Exchange Name Security Exchange Name 2022 Binding Letter Agreement Binding Letter Agreement 2022 [Member] The name of binding letter of agreement with FFB and the Jaeb Center for Health Research ("JCHR") to collaborate on natural history studies involving individuals with retinal dystrophies associated with mutations in multiple genes of interest. Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] R&D services and supplies Accrued Research And Development Services and Supplies Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development service and supplies. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Unpaid issuance costs Unpaid Issuance Costs Unpaid issuance costs related to equity transactions. Weighted average grant price (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable in Period Weighted Average Grant Date Fair Value The weighted average fair value at exercisable date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans. Total financial liabilities at fair value Liabilities, Fair Value Disclosure Entity Shell Company Entity Shell Company Fair value change reported in statements of operations Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Milestone payments received Milestone Payments Received The milestone payment amount received upon the achievement of development, regulatory and commercial goals under the agreement. Granted stock awards for services performed (in shares) Stock Issued During Period, Shares, Issued for Services Segment Information Segment Reporting, Policy [Policy Text Block] Net Loss per Share Earnings Per Share [Text Block] Reclassification of warrant liability upon exercise Reclassification Of Warrant Liability Upon Exercise Reclassification Of Warrant Liability Upon Exercise Name Outstanding Recovery, Individual Name Net loss per share: Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Interest payments Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Interest Payments Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Interest Payments Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol SBIR Grant Agreement SBIR Grant Agreement [Member] Small Business Innovation Research ("SBIR") grant through the Department of Health and Human Services Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Sublicense Agreement [Abstract] Sublicense Agreement [Abstract] Sublicense Agreement [Abstract] Number of shares converted (in shares) Convertible Preferred Stock, Shares Issued upon Conversion Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Deferred compensation matched by employer, first match Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Convertible Senior Notes Due 2033 Convertible Senior Notes Due 2033 [Member] Convertible Senior Notes Due 2033 Threshold trading days above $1.75 per share or daily volume above $150,000 Class Of Warrant Or Right, Threshold Trading Days Above $1.75 Per Share Or Daily Volume Above $150,000 Class Of Warrant Or Right, Threshold Trading Days Above $1.75 Per Share Or Daily Volume Above $150,000 Company Selected Measure Name Company Selected Measure Name Sale of Stock [Domain] Sale of Stock [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Stock Issued During Period Shares, Exercise of Warrants Stock Issued During Period Shares, Exercise of Warrants Number of shares issued after exercise of warrants. Earnings Per Share, Diluted [Abstract] Earnings Per Share, Diluted [Abstract] Supplemental non-cash financing transactions: Noncash Investing and Financing Items [Abstract] Percentage of royalty payment obligation Percentage of Royalty Payment Obligation The aggregate percentage of royalty obligation equals to the amounts funded by RDF under the RDF agreement that serves as the cap for total royalty payments owed by the company to RDF. Related Party Transactions [Abstract] Related Party Transactions [Abstract] Operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Massachusetts Eye and Ear Infirmary License Agreement Massachusetts Eye and Ear Infirmary License Agreement [Member] Opus entered into a license agreement (the "MEEI License") with the Massachusetts Eye and Ear Infirmary ("MEEI"), granting an exclusive worldwide license of MEEI patents for use in the NMNAT1 program for all products and processes including the treatment of retinal disease in humans, and a non-exclusive worldwide license to technological information. Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Warrants Warrant [Member] Diluted weighted average shares outstanding (in shares) Diluted weighted average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Fourth Tranche Fourth Tranche [Member] Fourth Tranche Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Dr. George Magrath [Member] Dr. George Magrath Line of Credit Facility [Table] Line of Credit Facility [Table] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Temporary Equity Disclosure [Abstract] Temporary Equity Disclosure [Abstract] Expiration period Class of Warrant or Right, Expiration Period Class of Warrant or Right, Expiration Period Exercise price (in USD per share) Stock Option, Exercise Price Stock Option, Exercise Price Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Revenue from Contract with Customer [Abstract] Penn and UF RHO License Agreement Penn and UF RHO License Agreement [Member] Iveric entered into an exclusive patent license agreement (the "RHO License") by and between Penn and UF pursuant to which the Company has exclusive patent rights and non-exclusive knowhow and data rights with regard to products to treat rhodopsin-mediated diseases as a result of the Iveric Agreement. Second Tranche Second Tranche [Member] Second Tranche Award Timing Predetermined Award Timing Predetermined [Flag] Weighted average grant date fair value (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Services, Grants in Period, Weighted Average Grant Date Fair Value The weighted average grant-date fair value of stock award granted for services during the reporting period as calculated by applying the disclosed option pricing methodology. Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition 401K Plan Retirement Plan, 401K [Member] A defined-contribution retirement account which allows employees to save a portion of their salary in a tax-advantaged manner. The money earned in a 401(k) Plan is not taxed until after the employee retires, at which time their income will typically be lower than during their working years. Level 1 Fair Value, Inputs, Level 1 [Member] Proceeds from Warrant Exercises Proceeds from Warrant Exercises Effective income tax rate reconciliation, percent Effective Income Tax Rate Reconciliation, Percent Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Potential payment of additional installment Payment of Additional Installment to Support Study under Agreement Potential additional installment payment related to the Foundation Fighting Blindness Retinal Degeneration Fund agreement. Dilutive effect of March 2025 warrants and March 2025 private placement warrants (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Milestone payment requirements attributed to the FDA's approval Milestone Payment Required Under FDA's Approval The amount of milestone payment met by the entity which required FDA's approval. Adjustments to additional paid in capital, convertible debt with conversion feature Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature Weighted average grant price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value All Executive Categories All Executive Categories [Member] Dr. George Magrath Chief Executive Officer [Member] Employer matching contribution, first match Defined Contribution Plan, Employer Matching Contribution, Percent of Match Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Interest paid in kind percent Debt Instrument, Interest Rate, Paid In Kind, Percent Debt Instrument, Interest Rate, Paid In Kind, Percent Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Preferred stock par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Notes Long-Term Debt, Fair Value Depreciation Depreciation Sales Milestones Sales Milestones [Member] Represents sales milestones. Plan Name [Domain] Plan Name [Domain] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Exercise Price $0.95 Warrant Exercise Price One [Member] The exercise price range of warrant one. RDO Warrants RDO Warrants [Member] Registered Direct Offering (RDO) warrants. Scenario [Domain] Scenario [Domain] Warrants Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Payments due related to amount funded to support study Payments Due Related to Amount Funded to Support Study The payable amount related to funded to support the study due under the 2022 Binding Letter Agreement. Number of securities to purchase in each share of common stock and warrant (in shares) Number of Securities to Purchase in Each Share of Common Stock and Warrant Number of securities issued for each share of common stock and warrant. Exercised (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Exercised in Period, Exercise Price Per Warrant The exercise price per warrant at exercised date for nonvested equity-based awards issued during the period on other than stock. Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Debt Disclosure [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Minimum Minimum [Member] Expiration Date Trading Arrangement Expiration Date 2030 Long-Term Debt, Maturity, Year Four Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Location, Statement of Income, Balance [Axis] Location, Statement of Income, Balance [Axis] First Tranche First Tranche [Member] First Tranche Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Funded amount to support study payable in annual installment Amount Funded to Support Study, Payable in Annual Installment The amount funded to support the study payable in annual installment. Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Liquidity Liquidity [Policy Text Block] Disclosure of accounting policy for the liquidity. Nonrelated Party Nonrelated Party [Member] Stock issued, issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Proceeds from issuance of common stock in connection with the at-the-market program and purchase agreement Proceeds from Issuance of Common Stock Common stock authorized (in shares) Common Stock, Shares Authorized Issuance of March 2025 Warrants and March 2025 Private Placement Warrants Derivative Liability, Issuance of Warrants and Private Placement Warrants Amount of derivative liability of issuance of warrants and private placement warrants executed during the period. Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Exercise Price Award Exercise Price Investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Related Party Transaction [Axis] Related Party Transaction [Axis] Financings Financings [Text Block] The entire disclosure for information about financings. Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Financing costs Financing Costs Amount of expense associated with the equity purchase agreement during the current accounting period. Debt Debt Disclosure [Text Block] Scenario [Axis] Scenario [Axis] Schedule of Future Debt Payments Contractual Obligation, Fiscal Year Maturity [Table Text Block] Deferred Compensation Plan [Abstract] Deferred Compensation Arrangements [Abstract] Derivative Liability [Abstract] Derivative Liability [Abstract] Number of contingent value right received per common stock Contingent Value Right Entitled Per Each Share Of Common Stock Held Contingent value right per each share of the Company's common stock held of record as of immediately prior to the closing of the merger. Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Non-refundable cash payment received Non-refundable Cash Payment Received The amount of non-refundable cash payments received during the period under the collaboration agreement. Equity Component [Domain] Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Measurement Input Type [Domain] Measurement Input Type [Domain] Issuance costs related to common stock, note purchase agreement Adjustments To Additional Paid In Capital, Issuance Costs Related To Common Stock, Note Purchase Agreement Adjustments To Additional Paid In Capital, Issuance Costs Related To Common Stock, Note Purchase Agreement Sales of stock issued in transaction Sale of Stock, Consideration Received on Transaction Adoption Date Trading Arrangement Adoption Date March 2025 Warrants March 2025 Warrants [Member] A march 2025 warrant that allows the warrant holder to purchase a specified number of a company's securities at a initial exercise price. Proceeds from Issuance or Sale of Equity Proceeds from Issuance or Sale of Equity Apexian Sublicense Agreement Apexian Sublicense Agreement [Text Block] The entire disclosure for Apexian Sublicense Agreement related to exclusive worldwide patent and other intellectual property rights that constitute a Ref-1 Inhibitor program relating to therapeutic applications to treat disorders related to ophthalmic and diabetes mellitus conditions. Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Total stockholders’ (deficit) equity Beginning balance Ending balance Equity, Attributable to Parent Assets Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Risk free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Professional fees Professional Fees Payments of stock issuance costs Payments of stock issuance costs Payments of Stock Issuance Costs Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Proceeds from stock purchase and conversion agreement Proceeds From Issuance Of Common Stock And Pre-Funded Warrants In Connection With Stock Purchase And Conversion Agreement Proceeds From Issuance Of Common Stock And Pre-Funded Warrants In Connection With Stock Purchase And Conversion Agreement Prepaids and other current assets Prepaid Expense and Other Assets, Current Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Supplemental Balance Sheet Information Supplemental Balance Sheet Disclosures [Text Block] First milestone payments received First Milestone Payment Received The amount of milestone payment received upon achieving performance obligation. Business Combination [Domain] Business Combination [Domain] Subsequent Events [Abstract] Subsequent Events, Additional Information [Abstract] Subsequent Events, Additional Information [Abstract] Balance as of beginning of period Balance as of end of period Contract Asset, Current Amount, after allowance for credit loss, of right to consideration upon the completion of services to customer when right is conditioned on something other than passage of time, classified as current. Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Total Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of operating segments Number of Operating Segments Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Entity Central Index Key Entity Central Index Key Tranche [Domain] Tranche [Domain] Tranche [Domain] All Adjustments to Compensation All Adjustments to Compensation [Member] Business Combination [Axis] Business Combination [Axis] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation 2026 Long-Term Debt, Maturity, Remainder of Fiscal Year Income Statement [Abstract] Income Statement [Abstract] Stockholders’ (deficit) equity: Equity, Attributable to Parent [Abstract] Aggregate conversion percent Debt Instrument, Convertible, Aggregate Conversion Percent Debt Instrument, Convertible, Aggregate Conversion Percent Document Transition Report Document Transition Report Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Operating expenses: Operating Expenses [Abstract] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Maximum percentage of beneficial ownership limitation Maximum Percentage of Beneficial Ownership Limitation Maximum percentage of beneficial ownership allowed for warrant holder and affiliates in exercise of warrants. City Area Code City Area Code RSUs Restricted Stock [Member] Proceeds from issuance of warrants in connection with the March 2025 offering and March 2025 private placement Proceeds from Issuance of Warrants in Connection with Private Offering and Private Placement The cash inflow from issuance of rights to purchase common shares in connection with private offering and private placement. All Individuals All Individuals [Member] Subsequent Events Subsequent Events [Text Block] Expired (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Expired in Period, Exercise Price Per Warrant Exercise price per warrant as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. 2025 Letter Agreement Letter Agreement 2025 [Member] The name of a binding letter of agreement with FFB and the JCHR on portions of a study involving individuals with retinal dystrophies associated with mutations in the RDH12 or BEST1 genes (the "Study"). Commercial Milestones Commercial Milestones [Member] Represents commercial milestones. Name Forgone Recovery, Individual Name Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Exercise Price Per Warrant Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Exercised (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Grant Date Fair Value The weighted average fair value at exercised date for nonvested equity-based awards issued during the period on other than stock. Long-term debt measurement input Long-Term Debt, Measurement Input Statement [Line Items] Statement [Line Items] Total assets Assets Defined Benefit Plan [Table] Defined Benefit Plan [Table] Outstanding at end of period (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Nonvested, Exercise Price Per Warrant Per share or unit exercise price per warrant of nonvested award under share-based payment arrangement. Excludes share and unit options. Preferred stock issued (in shares) Preferred Stock, Shares Issued Convertible Debt Convertible Debt [Member] Trading volume during measurement period Threshold of Daily Trading Volume During Measurement Period Threshold amount of daily trading volume on each trading day during the measurement period. Proceeds from issuance of convertible preferred stock Proceeds from Issuance of Convertible Preferred Stock BEST1 Program BEST1 Program [Member] BEST1 is in development for the treatment of BEST1-associated retinal disease, an IRD that causes vision loss. Non-cash interest, related party Interest Expense, Nonoperating Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Conversion of preferred stock instruments Conversion of Stock, Amount Converted Stock-based Compensation Share-Based Payment Arrangement [Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Proceeds from convertible debt Proceeds from Convertible Debt Dr. Sally Tucker [Member] Dr. Sally Tucker Stock issued (in shares) Stock Issued During Period, Shares, New Issues PEO PEO [Member] 2028 Long-Term Debt, Maturity, Year Two Issuance of common stock in connection with the at-the-market program and purchase agreement (in shares) Stock Issued During Period Shares at-the-Market Program and Purchase Agreement Number of new stock issued in connection with the at-the-market program and purchase agreement during the period. Contract assets and unbilled receivables Increase (Decrease) in Contract Assets and Unbilled Receivables The increase (decrease) during the reporting period in contract assets and unbilled receivables arising from the contracting of goods and services and for work performed for which billing has not occurred, net for uncollectible accounts. Total stock-based compensation Share-Based Payment Arrangement, Expense Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Stock option exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issued (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Domain] Subsequent Event Type [Domain] Accumulated Deficit Retained Earnings [Member] Total operating expenses Operating Expenses Expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Series A Preferred Stock Series A Preferred Stock [Member] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock outstanding (in shares) Balance (in shares) Balance (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Issuance costs attributed to note purchase agreement Payments of debt issuance costs Payments of Debt Issuance Costs Period of agreement termination after study completion Period of Agreement Termination after Study Completion Period of agreement termination after study completion in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Diluted (in dollars per share) Earnings Per Share, Diluted Warrant liabilities Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Entity Current Reporting Status Entity Current Reporting Status Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Foundation Fighting Blindness Foundation Fighting Blindness [Member] This member stands for foundation fighting blindness. Opus Genetics, Inc. Opus Genetics, Inc. [Member] Name of the acquiring entity. Prepaids and other current assets Increase (Decrease) in Prepaid Expense and Other Assets BioSense License and Assignments Agreement BioSense License and Assignments Agreement [Member] BioSense license and assignments agreement entered by the entity. Unrealized loss from short-term investments Unrealized Gain (Loss) on Investments Fair Value, Liabilities Measured on Recurring Basis Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Research and Development Expense Research and Development Expense Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] 2029 Long-Term Debt, Maturity, Year Three Temporary equity, par value (in dollars per share) Temporary Equity, Par or Stated Value Per Share Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] License and collaborations revenue Revenue from Contract with Customer, Excluding Assessed Tax Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Shares issued, price per share (in dollars per share) Shares Issued, Price Per Share Exercisable (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Exercisable in Period, Exercise Price Per Warrant The exercise price per warrant at exercisable date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans. Exercised (in shares) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period The number of share options (or share units) exercised made during the period on other than stock (or unit) option plans. Financial Instruments [Domain] Financial Instruments [Domain] Share repurchases for the payment of employee taxes (in shares) Stock Repurchases for Payment of Employee Taxes, Shares Number of shares repurchases for the payment of employee taxes. Issued (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Issued in Period, Exercise Price Per Warrant The exercise price per warrant at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Share repurchases for the payment of employee taxes Share Repurchases for Payment of Employee Taxes Cash outflow for share repurchases for the payment of employee taxes. Number exercisable (in shares) Class of Warrant or Right Exercisable Number of warrants or rights exercisable during the period. Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Underlying Securities Award Underlying Securities Amount First Licensed Product First Licensed Product [Member] Information related first licensed product, regardless of category. 2018 Equity Incentive Plan Equity Incentive Plan 2018 [Member] Information related to 2018 equity incentive plan. Rexahn Rexahn stockholders [Member] Entity owned or controlled by another entity. Preferred Stock Preferred Stock [Member] Number of equal installments for vesting Share Based Compensation Arrangement By Share Based Payment Award Number Of Equal Installments For Awards To Vest The number of equal installments for share-based compensation awards to vest. Related Party Transaction [Table] Related Party Transaction [Table] Title and Position [Axis] Title and Position [Axis] Sale of Stock [Axis] Sale of Stock [Axis] Issuance of common stock in connection with at-the-market program Stock Issued During Period Value at-the-Market Program and Purchase Agreement Equity impact of the value of new stock issued in connection with the at-the-market program and purchase agreement during the period. Milestone payment receivable Milestone Payment Receivable The amount of milestone payment receivable under the agreement. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Fair value at April 21, 2026 (issuance) Fair value at June 30, 2026 Fair value of warrants Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Loss from operations Operating Income (Loss) Current Fiscal Year End Date Current Fiscal Year End Date Payments for CVR Payments due under CVR Agreement Number of payments were due under the CVR Agreement. Warrant liabilities Warrants and Rights Outstanding Warrant exercises Warrant Exercises Warrant Exercises Proceeds from funding agreement, related party Proceeds from Issuance of Debt Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Related Party Transaction [Domain] Related Party Transaction [Domain] Notes payable fair value Notes Payable, Fair Value Disclosure Issuance of shares in conversion of preferred shares (in shares) Temporary Equity, Stock Issued During Period, Value, New Issues Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Warrant Activity and Outstanding Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Conversion price denominator (in dollars per share) Debt Instrument, Convertible, Conversion Price Denominator Debt Instrument, Convertible, Conversion Price Denominator Payment of initial installment Payment of Initial Installment to Support Study under Agreement Payment of initial installment amount related to the Foundation Fighting Blindness agreement. Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Number of RDO warrants sold at offering price (in shares)) Number of RDO Warrants Sold at Offering Price Number of registered direct offering warrants sold at offering price (per unit). Consecutive trading days Number of Consecutive Trading Days Number of consecutive trading days in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Equity Components [Axis] Equity Components [Axis] Purchase And Conversion Agreement Purchase And Conversion Agreement [Member] Purchase And Conversion Agreement Accounts receivable Increase (Decrease) in Accounts Receivable Temporary equity, issuance costs Temporary Equity, Issuance Costs Temporary Equity, Issuance Costs Share-Based Payment Arrangement, Recognized Amount [Abstract] Share-Based Payment Arrangement, Recognized Amount [Abstract] Product and Service [Domain] Product and Service [Domain] Related Party Related Party [Member] Issuance costs Adjustments to Additional Paid in Capital, Issuance Costs related to Common Stock, ATM and Registered Direct Financing Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock and . Includes, but is not limited to, legal and accounting fees and direct costs associated with common stock; ATM and Registered Direct Financing. Stock Conversion Description [Axis] Stock Conversion Description [Axis] Entity Interactive Data Current Entity Interactive Data Current Long-Term Debt Long-Term Debt [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Small Business Entity Small Business Tranche [Axis] Tranche [Axis] Tranche Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Rob Gagnon [Member] Rob Gagnon Termination Date Trading Arrangement Termination Date Subsequent Events [Abstract] Subsequent Events [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Number of potential milestones Number Of Potential Milestones Number of potential milestones had been accrued during the period. MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Financings [Abstract] Financings [Abstract] Financings [Abstract] Document Type Document Type Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value as of Grant Date Award Grant Date Fair Value Minimum percentage of beneficial ownership Minimum Percentage of Beneficial Ownership Minimum percentage of beneficial ownership allowed for warrant holder and affiliates in exercise of warrants. Paid-in-kind interest on outstanding Notes Paid-in-Kind Interest Registered Direct Offering Registered Direct Offering [Member] A Registered Direct Offering is an offering of securities that has been registered with the Securities and Exchange Commission (SEC) to pre-identified investors. Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Subsequent Event [Line Items] Subsequent Event [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Temporary equity, shares authorized (in shares) Temporary Equity, Shares Authorized Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Number of milestones accrued Number of Milestones Accrued Number of milestones had been accrued during the period. Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Expiration period Warrants and Rights Outstanding, Term Commitments and contingencies (Note 4 and Note 11) Commitments and Contingencies Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] November 2025 Registered Direct Offering November 2025 Registered Direct Offering [Member] The November 2025 Registered Direct Offering is an offering of securities that has been registered with the Securities and Exchange Commission (SEC) to pre-identified investors. Liabilities, convertible preferred stock and stockholders’ (deficit) equity Liabilities and Equity [Abstract] Beginning balance Ending balance Temporary Equity, Carrying Amount, Attributable to Parent Maximum amount of nondilutive funding milestone payments Maximum Amount of Nondilutive Funding Milestone Payments The maximum amount of nondilutive funding milestone payments under the agreement to support the development of the Mer proto-oncogene tyrosine kinase gene Program. Equity Award [Domain] Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Class of Warrant or Right, Outstanding Number outstanding (in shares) Class of Warrant or Right, Outstanding Fair Value Measurements Fair Value Disclosures [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Common stock market price per share (in dollars per share) Share Price Issuance of common stock and pre-funded warrants in connection with the March 2025 offering and private placement (in shares) Stock Issued During Period Shares of Private Offering and Private Placement Number of new stock issued in connection with private offering and private placement during the period. PEO Name PEO Name Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information [Abstract] Share repurchases for the payment of employee taxes Adjustments To Additional Paid In Capital Share Repurchases For Payment Of Employee Taxes Amount of decrease in additional paid in capital (APIC) resulting from share repurchases for the payment of employee taxes. Accrued expenses Total Accrued Liabilities and Other Liabilities Temporary equity, shares issued (in shares) Temporary Equity, Shares Issued Retirement Plan Name [Domain] Retirement Plan Name [Domain] Conversion of Series B preferred stock to common stock Temporary Equity, Value, Conversion Of Convertible Securities Temporary Equity, Value, Conversion Of Convertible Securities Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Conversion term Debt Instrument, Convertible, Conversion Term Debt Instrument, Convertible, Conversion Term Entity Tax Identification Number Entity Tax Identification Number Cam Gallagher Chairman of the Board [Member] chairman of the Board Interest Expense, Debt Interest Expense, Debt Liability Class [Axis] Liability Class [Axis] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Axis] Maximum percentage of tiered royalties receivable Maximum Percentage of Tiered Royalties Receivable The maximum percentage of tiered royalties receivable based on the aggregate annual net sales of all Nyxol Products in the United States. Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Development and Regulatory Milestones Development and Regulatory Milestones [Member] Represents development and regulatory milestones. Professional services Accrued Professional Fees, Current Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accounts payable Increase (Decrease) in Accounts Payable Other Other Accrued Liabilities, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Exercise Price $1.15 Warrant Exercise Price Two [Member] The exercise price range of warrant two. Interest paid in cash percent Debt Instrument, Interest Rate, Paid In Cash, Percent Debt Instrument, Interest Rate, Paid In Cash, Percent Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Final installment payable upon receipt of semi-annual reports of study Final Installment Payable upon Receipt of Semi-annual Reports of Study The final installment amount funded to support the study payable upon upon receipt of semi-annual reports. Restricted cash Restricted Cash and Cash Equivalent, Current Conversion of convertible securities (in shares) Temporary Equity, Shares, Conversion Of Convertible Securities Temporary Equity, Shares, Conversion Of Convertible Securities Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Contract assets and unbilled receivables (Note 12) Contract Assets and Unbilled Receivables, Current Contract assets and unbilled receivables are recognized when goods or services are transferred to the customer before the customer pays or before reimbursement for payment is billed or due, excluding any amounts presented as an account receivable, for contractual agreements due within one year or the normal operating cycle, if longer. Debt Instrument [Axis] Debt Instrument [Axis] Subsequent Event [Table] Subsequent Event [Table] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Conversion of preferred stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities 2027 Long-Term Debt, Maturity, Year One Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Basic (in dollars per share) Earnings Per Share, Basic Measurement Input Type [Axis] Measurement Input Type [Axis] Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Long-term debt Long-Term Debt, Excluding Current Maturities Award Type [Axis] Award Type [Axis] Rent expense Short-Term Lease, Cost Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Accumulated deficit Retained Earnings (Accumulated Deficit) Product and Service [Axis] Product and Service [Axis] Restricted cash Restricted Cash, Noncurrent Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Expected volatility rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Viatris License Agreement Viatris License Agreement [Member] Viatris license and agreement entered by the entity. Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Company Description and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Cover [Abstract] Cover [Abstract] Series B Preferred Stock Series B Preferred Stock [Member] March 2025 Private Placement Warrants March 2025 Private Placement Warrants [Member] A march 2025 private placement warrants that allows the warrant holder to purchase a specified number of a company's securities at a initial exercise price. Equity Awards Adjustments Equity Awards Adjustments [Member] Authorized amount Sale Of Stock, Authorized Amount Sale Of Stock, Authorized Amount Funded amount to support study payable in initial installment Amount Funded to Support Study, Payable in Initial Installment The amount funded to support the study payable in initial installment at the time of the agreement. License and Collaboration Revenue and Other Funding Agreements Collaborative Arrangement Disclosure [Text Block] Total liabilities, convertible preferred stock and stockholders’ (deficit) equity Liabilities and Equity Warrant liabilities Derivative Liability, Noncurrent Number of shares issued upon conversion (in shares) Preferred Stock, Convertible, Shares Issuable Stock options Share-Based Payment Arrangement, Option [Member] Issuance of Series B preferred stock, (in shares) Temporary Equity, Stock Issued During Period, Shares, New Issues Temporary Equity, Stock Issued During Period, Shares, New Issues Proceeds from issuance of Series B preferred stock Proceeds from Issuance of Preferred Stock and Preference Stock Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Plan Name [Axis] Plan Name [Axis] Related and Nonrelated Parties [Domain] Related and Nonrelated Parties [Domain] Tabular List, Table Tabular List [Table Text Block] Buyout interest in entity equals percentage of disbursed funds Buyout Interest Equals Percentage of Disbursed Funds, in Event of Change of Control or Sale or License Buyout interest in entity equals to the percentage of disbursed funds, in the event of a change of control of the Company or a sale or exclusive license of the MERTK Program. Additional paid-in capital Additional Paid in Capital Other income, net Other Nonoperating Income (Expense) Accrued Expenses and Other liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Name Awards Close in Time to MNPI Disclosures, Individual Name Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Additional employer matching contribution Defined Contribution Plan, Additional Employer Matching Contribution Additional percentage employer matches of the employee's percentage contribution matched. General and administrative General and Administrative Expense Price per share (in USD per share) Sale of Stock, Price Per Share BEST1 License Agreement Penn and University of Florida BEST1 License Agreement [Member] Iveric entered into an exclusive patent license agreement (as amended, the "BEST1 License") with Penn and the University of Florida Research Foundation ("UF"), which agreement was assigned to Opus under the terms of the Iveric Agreement. Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Conversion of preferred stock Stock Issued During Period, Value, Conversion of Convertible Securities Preferred stock authorized (in shares) Preferred Stock, Shares Authorized Accrued Liabilities and Other Liabilities [Abstract] Accrued Liabilities and Other Liabilities [Abstract] Preferred stock, par value $0.0001; 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 0 shares issued and outstanding at June 30, 2026 and December 31, 2025. Preferred Stock, Value, Issued Adjustment to Compensation: Adjustment to Compensation [Axis] Proceeds from issuance of common stock and pre-funded warrants in connection with the March 2025 offering and March 2025 private placement Proceeds from Issuance of Common Stock and Pre-funded Warrants in Connection with Private Offering and Private Placement The cash inflow from the additional capital contribution to the entity in connection with private offering and private placement. Offering price (in dollars per share) Stock Sold, Price Per Share Per share amount received for each share of common stock issued or sold in the stock transaction. Warrant Liabilities Derivative Financial Instruments, Liabilities [Member] Class of Stock [Domain] Class of Stock [Domain] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activity Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Name Measure Name Income Taxes Income Tax Disclosure [Text Block] Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] RDH12 Agreement RDH12 Agreement [Member] The Funding and License Agreement dated July 22, 2025, among the Company, its wholly owned subsidiary OpusTX, LLC (together, "Opus"), Eyes on the Future, and the RDH12 Fund. RDF Agreement Foundation Fighting Blindness Retinal Degeneration Fund Agreement [Member] The name of a funding agreement with Foundation Fighting Blindness Retinal Degeneration Fund to develop gene therapies to treat patients impacted by retinitis pigmentosa caused by pathogenic variants in the Mer proto-oncogene tyrosine kinase (MERTK) gene (the "MERTK Program"). Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional Paid–In Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Dr. Pepose Director [Member] Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and Cash Equivalent Weighted average price volume duration Debt Instrument, Convertible, Weighted Average Price Volume Duration Debt Instrument, Convertible, Weighted Average Price Volume Duration Fair value change in instruments measured at fair value, net of cash interest paid of $281 Gain (Loss) on Derivative Instruments, Net, Pretax Company Selected Measure Amount Company Selected Measure Amount Milestone payments received Milestone Payments Amount Received The amount of milestone payment received upon achieving performance obligation.. Development, Regulatory and Commercial Milestone Development, Regulatory and Commercial Milestone [Member] Represents development, regulatory and commercial milestone. LCA5/RDH12 Agreement University of Pennsylvania LCA5/RDH12 License Agreement [Member] Opus entered into an amended and restated license agreement (the "LCA5/RDH12 Agreement") with the Trustees of the University of Pennsylvania ("Penn") pursuant to which it was granted an exclusive, royalty-bearing license to certain patents and a non-exclusive license to certain information relating to products directed towards treatment or correction of mutation of the LCA5 or RDH12 genes. Cash cash equivalents and restricted cash Cash and Cash Equivalents Disclosure [Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Stock-based compensation (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Retirement Plan Name [Axis] Retirement Plan Name [Axis] Underwritten Public Offering Underwritten Public Offering [Member] A public offering in which common stock is offered and sold on a firm commitment basis through one or more underwriters, all pursuant to (i) an effective registration statement under the Securities Act and (ii) an underwriting agreement between the Company and such underwriters. 2031 Long-Term Debt, Maturity, Year Five Current assets: Assets, Current [Abstract] Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Benefit (provision) for income taxes Income tax benefit Income Tax Expense (Benefit) Series A Preferred Stock [Abstract] Preferred Stock Series A [Abstract] Preferred Stock Series A [Abstract] ATM At-The-Market Program [Member] At-the-market is an instruction given to a broker to place a market order to buy or sell securities at the prevailing market bid or ask price during the period. Type of Arrangement [Abstract] Type of Arrangement [Abstract] Type of Arrangement [Abstract] Award Timing Method Award Timing Method [Text Block] Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forecast Forecast [Member] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Net Income (Loss) Attributable to Parent [Abstract] Net Income (Loss) Attributable to Parent [Abstract] Non-cancellation period of Constraint for Research and Development Revenue Non-cancellation Period of Constraint for Research and Development Revenue Non-cancellation period of constraint for Recognizing Research and Development Revenue, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Preferred Stock Temporary Equity Disclosure [Text Block] The entire disclosure for temporary equity. Pre-Funded Warrants Pre-Funded Warrants [Member] A pre-funded warrant that allows the warrant holder to purchase a specified number of a company's securities at a nominal exercise price. Research and development Research and Development Expense (Excluding Acquired in Process Cost) Net loss Net and comprehensive loss Net loss Net Income (Loss) Attributable to Parent Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Valuation Technique, Discounted Cash Flow Valuation Technique, Discounted Cash Flow [Member] Statement [Table] Statement [Table] Restatement Determination Date: Restatement Determination Date [Axis] Additional deferred compensation matched by employer Defined Contribution Plan, Additional Employer Matching Contribution Deferred Additional percentage employer matches of the employee's deferred percentage contribution matched. Exercise of stock options Proceeds from Stock Options Exercised Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Milestone payments Future Milestone Method, Revenue not Recognized The amount of consideration not recognized during the period for the future milestone or milestones. Proceeds from note purchase agreement Proceeds From Issuance Of Common Stock And Pre-Funded Warrants In Connection With Note Purchase Agreement Proceeds From Issuance Of Common Stock And Pre-Funded Warrants In Connection With Note Purchase Agreement Change in fair value reported in other comprehensive loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Apexian Sublicense Agreement [Abstract] Apexian Sublicense Agreement [Abstract] Apexian Sublicense Agreement [Abstract]